Faber, Jens

Plasma Adiponectin, Body Mass Index, and Mortality in Patients With Chronic Heart Failure

Kistorp, C., Faber, J., Galatius, S., Gustafsson, F., Frystyk, J., Flyvbjerg, A., & Hildebrandt, P. (2005) · Circulation

Heart Failure Treatment and ManagementAdipokines, Inflammation, and Metabolic Diseases

Cited by 605

Changes in bone mass during prolonged subclinical hyperthyroidism due to l-thyroxine treatment: a meta-analysis

Faber, J., & Galløe, A. M. (1994) · European Journal of Endocrinology

Thyroid Disorders and TreatmentsBone health and osteoporosis research

Cited by 377

The spectrum of thyroid disease and risk of new onset atrial fibrillation: a large population cohort study

Selmer, C., Olesen, J. B., Hansen, M. L., Lindhardsen, J., Olsen, A.-M. S., Madsen, J. C., Faber, J., Hansen, P. R., Pedersen, O. D., Torp-Pedersen, C., et al. (2012) · BMJ

Thyroid Disorders and TreatmentsAtrial Fibrillation Management and Outcomes

Cited by 323

Subclinical and Overt Thyroid Dysfunction and Risk of All-Cause Mortality and Cardiovascular Events: A Large Population Study

Selmer, C., Olesen, J. B., Hansen, M. L., von Kappelgaard, L. M., Madsen, J. C., Hansen, P. R., Pedersen, O. D., Faber, J., Torp-Pedersen, C., & Gislason, G. H. (2014) · The Journal of Clinical Endocrinology & Metabolism

Thyroid Disorders and TreatmentsThyroid and Parathyroid Surgery

Cited by 288

Effect of liraglutide on ectopic fat in polycystic ovary syndrome: Arandomized clinical trial

Frøssing, S., Nylander, M., Chabanova, E., Frystyk, J., Holst, J. J., Kistorp, C., Skouby, S. O., & Faber, J. (2018) · Diabetes, Obesity and Metabolism

Ovarian function and disordersLiver Disease Diagnosis and Treatment

Cited by 178

Effect of combination therapy with thyroxine (T4) and 3,5,3′-triiodothyronine versus T4 monotherapy in patients with hypothyroidism, a double-blind, randomised cross-over study

Nygaard, B., Jensen, E. W., Kvetny, J., Jarløv, A., & Faber, J. (2009) · European Journal of Endocrinology

Thyroid Disorders and TreatmentsThyroid and Parathyroid Surgery

Cited by 153

Effects of liraglutide on ovarian dysfunction in polycystic ovary syndrome: a randomized clinical trial

Nylander, M., Frøssing, S., Clausen, H. V., Kistorp, C., Faber, J., & Skouby, S. O. (2017) · Reproductive BioMedicine Online

Ovarian function and disordersDiabetes, Cardiovascular Risks, and Lipoproteins

Cited by 139

Impact of Finerenone-Induced Albuminuria Reduction on Chronic Kidney Disease Outcomes in Type 2 Diabetes: A Mediation Analysis

Agarwal, R., Tu, W., Farjat, A. E., Farag, Y. M. K., Toto, R., Kaul, S., Lawatscheck, R., Rohwedder, K., Ruilope, L. M., Rossing, P., et al. (2023) · Annals of Internal Medicine

Chronic Kidney Disease and DiabetesHormonal Regulation and Hypertension

Cited by 109

Haemodynamic changes following treatment of subclinical and overt hyperthyroidism

Faber, J., Wiinberg, N., Schifter, S., & Mehlsen, J. (2001) · European Journal of Endocrinology

Thyroid Disorders and TreatmentsThyroid and Parathyroid Surgery

Cited by 104

Hypothyroid Patients Encoding Combined MCT10 and DIO2 Gene Polymorphisms May Prefer L-T3 + L-T4 Combination Treatment – Data Using a Blind, Randomized, Clinical Study

Carlé, A., Faber, J., Steffensen, R., Laurberg, P., & Nygaard, B. (2017) · European Thyroid Journal

Thyroid Disorders and TreatmentsThyroid Cancer Diagnosis and Treatment

Cited by 93

Transition of Nodular Toxic Goiter to Autoimmune Hyperthyroidism Triggered by 131I Therapy

NYGAARD, B., FABER, J., VEJE, A., HEGEDÜS, L., & HANSEN, J. M. (1999) · Thyroid

Thyroid Disorders and TreatmentsThyroid and Parathyroid Surgery

Cited by 84

Primary haemostasis in thyroid disease

MYRUP, B., BREGENGÅRD, C., & FABER, J. (1995) · Journal of Internal Medicine

Platelet Disorders and TreatmentsThyroid Disorders and Treatments

Cited by 72

Cardiovascular Events in Thyroid Disease: A Population Based, Prospective Study

Schultz, M., Kistorp, C., Raymond, I., Dimsits, J., Tuxen, C., Hildebrandt, P., & Faber, J. (2011) · Hormone and Metabolic Research

Thyroid Disorders and TreatmentsThyroid and Parathyroid Surgery

Cited by 67

Effects of liraglutide on cardiovascular risk biomarkers in patients with type 2 diabetes and albuminuria: Asub‐analysis of a randomized, placebo‐controlled, double‐blind, crossover trial

von Scholten, B. J., Persson, F., Rosenlund, S., Eugen‐Olsen, J., Pielak, T., Faber, J., Hansen, T. W., & Rossing, P. (2017) · Diabetes, Obesity and Metabolism

Diabetes Treatment and ManagementChronic Kidney Disease and Diabetes

Cited by 60

Treating Hypothyroidism with Thyroxine/Triiodothyronine Combination Therapy in Denmark: Following Guidelines or Following Trends?

Michaelsson, L. F., Medici, B. B., la Cour, J. L., Selmer, C., Røder, M., Perrild, H., Knudsen, N., Faber, J., & Nygaard, B. (2015) · European Thyroid Journal

Thyroid Disorders and TreatmentsThyroid and Parathyroid Surgery

Cited by 57

Liraglutide in polycystic ovary syndrome: a randomized trial, investigating effects on thrombogenic potential

Nylander, M., Frøssing, S., Kistorp, C., Faber, J., & Skouby, S. O. (2017) · Endocrine Connections

Ovarian function and disordersVenous Thromboembolism Diagnosis and Management

Cited by 44

Effect of liraglutide on atrial natriuretic peptide, adrenomedullin, and copeptin in PCOS

Frøssing, S., Nylander, M., Kistorp, C., Skouby, S. O., & Faber, J. (2018) · Endocrine Connections

Ovarian function and disordersDiabetes, Cardiovascular Risks, and Lipoproteins

Cited by 38

The effects of phenytoin (diphenylhydantoin) on the extrathyroidal turnover of thyroxine, 3,5,3′-triiodothyronine, 3,3′,5′-triiodothyronine, and 3′,5′-diiodothyronine in man

FABER, J., LUMHOLTZ, I. B., KIRKEGAARD, C., POULSEN, S., JØRGENSEN, P. H., NIELSEN, K. S., & FRIIS, T. (1985) · The Journal of Clinical Endocrinology & Metabolism

Thyroid Disorders and TreatmentsAdrenal Hormones and Disorders

Cited by 34

Prevalence and characteristics of diabetic patients in a chronic heart failure population

Kistorp, C., Galatius, S., Gustafsson, F., Faber, J., Corell, P., & Hildebrandt, P. (2005) · International Journal of Cardiology

Heart Failure Treatment and ManagementCardiovascular Function and Risk Factors

Cited by 33

GH activity and markers of inflammation: a crossover study in healthy volunteers treated with GH and a GH receptor antagonist

Andreassen, M., Frystyk, J., Faber, J., & Kristensen, L. O. (2012) · European Journal of Endocrinology

Growth Hormone and Insulin-like Growth FactorsAdipokines, Inflammation, and Metabolic Diseases

Cited by 33

Incidence rate of symptomatic painless thyroiditis presenting with thyrotoxicosis in Denmark as evaluated by consecutive thyroid scintigraphies

Schwartz, F., Bergmann, N., Zerahn, B., & Faber, J. (2013) · Scandinavian Journal of Clinical and Laboratory Investigation

Thyroid Disorders and TreatmentsThyroid Cancer Diagnosis and Treatment

Cited by 32

Cardiac natriuretic peptides in plasma increase after dietary induced weight loss in obesity

Kistorp, C., Bliddal, H., Goetze, J. P., Christensen, R., & Faber, J. (2014) · BMC Obesity

Heart Failure Treatment and ManagementCardiovascular Function and Risk Factors

Cited by 31

Levothyroxine/Liothyronine Combination Therapy and Quality of Life: Is It All about Weight Loss?

Michaelsson, L. F., la Cour, J. L., Medici, B. B., Watt, T., Faber, J., & Nygaard, B. (2018) · European Thyroid Journal

Thyroid Disorders and TreatmentsThyroid and Parathyroid Surgery

Cited by 30

Neither Baseline nor Changes in Serum Triiodothyronine during Levothyroxine/Liothyronine Combination Therapy Predict a Positive Response to This Treatment Modality in Hypothyroid Patients with Persistent Symptoms

Medici, B. B., la Cour, J. L., Michaelsson, L. F., Faber, J. O., & Nygaard, B. (2017) · European Thyroid Journal

Thyroid Disorders and TreatmentsThyroid and Parathyroid Surgery

Cited by 25